RegulatoryJun 2, 2026, 03:41 PM
PDS Biotechnology Regains Nasdaq Minimum Bid Price Compliance
AI Summary
PDS Biotechnology Corporation announced that it has regained compliance with Nasdaq's minimum bid price requirement. The company previously received a deficiency letter on February 25, 2026, due to its common stock trading below $1.00 for 30 consecutive business days. Nasdaq has now confirmed that PDS Biotechnology meets the requirement and has closed the matter.
Key Highlights
- PDS Biotechnology received a deficiency letter from Nasdaq on February 25, 2026, for failing to meet the $1.00 minimum bid price requirement.
- The company's common stock closing bid price was below $1.00 for 30 consecutive business days.
- The minimum bid price requirement is mandated by Nasdaq Listing Rule 5550(a)(2).
- On June 2, 2026, PDS Biotechnology received written notice from Nasdaq.
- Nasdaq informed the company that it has regained compliance with the Minimum Bid Price Requirement.
- Nasdaq has officially closed the matter regarding the listing deficiency.
Price Impact
More from PDSB